Андрология и генитальная хирургия. 2013; 14: 58-64
Показатели центральной гемодинамики и андрогенного статуса у мужчин с ишемической болезнью сердца и андрогенным дефицитом при его коррекции введением пролонгированного тестостерона
https://doi.org/10.17650/2070-9781-2013-4-58-64Аннотация
Целью работы является изучение динамики показателей центральной гемодинамики у мужчин с ишемической болезнью сердца, стабильной стенокардией напряжения, ожирением и андрогенным дефицитом на фоне заместительной терапии тестостерона ундеканоатом (ТУ). Проведена сравнительная оценка показателей центральной гемодинамики (ударный объем (УО), фракция выброса, конечно-систолический объем (КСО) и размер и конечно-диастолический объем (КДО) и размер) и андрогенного статуса у 2 групп мужчин: получавших (основная группа) и не получавших (контрольная группа) заместительную терапию ТУ. По итогам работы в основной группе, в отличие от контрольной группы, выявлена положительная тенденция в динамике ряда вышеперечисленных показателей (УО, КСО, КДО). Положительная динамика отдельных параметров центральной гемодинамики даже при кратковременной заместительной терапии ТУ указывает на терапевтический потенциал тестостерона при сердечно-сосудистой патологии, для полной реализации которого требуется, по-видимому, более продолжительная терапия.
Список литературы
1. Оганов Р. Г., Масленникова Г. Я. Эпидемию сердечно-сосудистых заболеваний можно остановить усилением профилактики. Проф мед 2009;6:3–7.
2. Barrett-Connor E., Khaw K. T. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988;78(3):539–45.
3. Vikan T., Schirmer H., Njølstad I., Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromsø Study. Eur J Endocrinol
4. ;161(3):435–42.
5. Shabsigh R., Katz M., Yan G., Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 2006;96(12):67–72.
6. Corona G., Forti G., Maggi M. Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male 2008;11(4):193–9.
7. Зилов А. В., Шейлор И. М., Гусова А. А. Возрастной гипогонадизм. Особенности диагностики, клиники и лечения. Фарматека 2007;11:38–43.
8. Shabsigh R., Rajfer J., Aversa A. et al. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006;60(9):1087–92.
9. Alexandersen P., Haarbo J., Byrjalsen I. et al. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 1999;84(7):813–9.
10. Jones R. D. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs 2005;5(3):141–54.
11. Mohr B. A., Guay A. T., O'Donnell A. B., McKinlay J. B. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf)
12. ;62(1):64–73.
13. Гончаров Н. П. Современные методы гормонального анализа. Пробл эндокринол 2011;57(1):86–91.
14. Гончаров Н. П., Кация Г. В. Диагностическая значимость определения общего тестостерона в сыворотке и свободного биологически активного тестостерона в слюне у мужчин. Пробл эндокринол 2007;53(3):30–5.
15. Гончаров Н. П. Значение и роль методов определения гормонов в развитии эндокринологии как общебиологической науки. Вестн РАМН 2012;3:42–9.
16. Гончаров Н. П., Кация Г. В., Колесникова Г. С., Добрачева А. Д. Гормональный анализ в диагностике болезней эндокринных желез. М.: АдамантЪ, 2009. С. 328.
17. Traish A. M., Kypreos K. E. Testosterone and cardiovascular disease: an old idea with modern clinical implications. Atherosclerosis 2011;214(2):244–8.
18. Wranicz J. K., Rosiak M., Cygankiewicz I. et al. Sex steroids and heart rate variability in patients after myocardial infarction. Ann Noninvasive Electrocardiol 2004;9(2):156–61.
19. Jankowska E. A., Biel B., Majda J. et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006;114(17):1829–37.
20. Gyllenborg J., Rasmussen S. L., Borch-Johnsen K. et al. Cardiovascular risk factors in men: The role of gonadal steroids and sex hormone-binding globulin. Metabolism 2001;50(8):882–8.
21. Гончаров Н. П., Кация Г. В., Чагина Н. А. Ожирение и формирование метаболического синдрома у молодых мужчин с развитием андрогенного дефицита. Вестн РАМН 2009;7:20–6.
22. Tsai E. C. Low serum testosterone level as a predictor of increased visceral fat in Japenes-American men. Int J Obes Relat Metab Disord 2000;24:485–91.
23. Malkin C. J. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96(22):1821–5.
24. Morales A., Lunenfeld B. Androgen replacement therapy in aging men with secondary hypogonadism. Draft recommendations for endorsement by ISSAM. Aging Male 2001;4:151–62.
25. Дедов И. И. Применение Небидо при синдроме гипогонадизма и его осложнениях у мужчин. Урология 2011;6:59–67.
26. Vermeulen A., Verdonck L., Kaufman J. M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–72.
27. Basaria S., Coviello A. D., Travison T. G. Adverse events associated with testosterone administration. N Engl J Med 2010;363(2):109–22.
28. Rosano G. M., Leonardo F., Pagnotta P. et al. Acute anti-ischaemic effect of testosterone in men with coronary artery disease. Circulation 1999;99:1666–70.
29. Кравченко А. Я., Провоторов В. М. Клинический эффект тестостерона при стабильной cтенокардии у мужчин. Рац фармакотер в кардиол 2009;1:37–41.
30. Pugh P. J. The prevalence of hypogonadism in men with coronary artery disease. J Am Coll Cardiol 2003;41:344–5.
31. Svartberg J., von Mühlen D., Schirmer H. et al. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø Study. Eur J Endocrinol 2004;150(1):65–71.
32. Giltay E. J., Tishova Y. A., Mskhalaya G. J. et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010;7(7):2572–82.
33. Moon du G., Park M. G., Lee S. W. et al. The efficacy and safety of testosterone undecanoate (Nebido (®) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med 2010;7(6):2253–60.
34. Legros J. J., Meuleman E. J., Elbers J. M. et al. Oral testosterone replacement in symptomatic late onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol 2009;160(5):821–31.
35. Morris P. D., Channer K. S. Testosterone and cardiovascular disease in men. Asian J Androl 2012;14(3):428–35.
36. Malkin C. J., Pugh P. J., Morris P. D. et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96:1821–5.
37. Pugh P. J., Jones T. H., Channer K. S. Acute haemodinamic effects of testosterone in men with chronic heart failure. Eur Heart J 2003;24:909–15.
38. Кравченко А. Я. Исследование влияния возрастного приобретенного андрогенодефицита на течение и особенности терапии сердечно-сосудистых заболеваний. Автореф. дис. … д-ра мед. наук. Воронеж, 2010. С. 30
39. Gruenewald D. A.,Matsumoto A. M. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 2003;51:101–5.
40. Allan C. A., McLachlan R. I. Age-related changes in testosterone and the role of replacement therapy in older men. Clin Endocrinol 2004;60:653–70.
41. Haffner J. E., Moss S. E., Klein B. E. K., Klein R. Sex hormones and DHEASO4 in relation to ischemic heart disease in diabetic subjects. The WESDR Study. Diabetes Care 1996;19:1045–50.
42. Liverman C. T., Blazer D. G. (eds.). Testosterone and aging: clinical research directions. Washington, DC: Institute of Medicine. The National Academies Press, 2004.
43. Phillips G., Pinkernell B. H., Jing T. Y. The association between hypotestosteronemia and coronary heart disease in men. Arterioscler Thromb 1994;14:701–6.
44. Cauley J. A., Gutai J. P., Kuller L. H., Dai W. S. Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol 1987;60:771–7.
45. Goldberg R. B., Rabin A. N., Alexander A. N. et al. Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and Apo A and B. J Clin Endocrinol Metab 1985;60:203–7.
46. Simon H. B. Testosterone – The 'Heart'of the Matter Last. Reviewed by Faculty of Harvard Medical School on January 2013;24.
47. Saad F., Aversa A., Isidori A. M. et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675–85.
Andrology and Genital Surgery. 2013; 14: 58-64
Central hemodynamics and androgen status in men with coronary heart disease, and androgen deficiency in its correction of prolonged administration of testosterone
https://doi.org/10.17650/2070-9781-2013-4-58-64Abstract
This work was designed to study the dynamic of the central hemodynamic disorders symptoms at men with coronary heart disease, stable angina, obesity and androgen deficiency under replacement short-term therapy by Testosterone undecanoate (TU). The comparative assessment of central hemodynamic indicators and total and sub-scale AMS score at two groups of men who receiving (the main group) and not receiving (control group) replacement therapy of TU is carried out. Results showed that in the main group, unlike control group the positive tendency in a number of indicators (stroke volume, left ventricular end- diastolic volume, left ventricular end- systolic volume) of the central hemodynamic and indicators of the androgenic status is observed. Positive dynamics of some parameters of the central hemodynamic even at short-term replacement therapy of TU indicates the therapeutic potential of testosterone at cardiovascular pathology which full realization may require longer period of testosterone administration.
References
1. Oganov R. G., Maslennikova G. Ya. Epidemiyu serdechno-sosudistykh zabolevanii mozhno ostanovit' usileniem profilaktiki. Prof med 2009;6:3–7.
2. Barrett-Connor E., Khaw K. T. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988;78(3):539–45.
3. Vikan T., Schirmer H., Njølstad I., Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromsø Study. Eur J Endocrinol
4. ;161(3):435–42.
5. Shabsigh R., Katz M., Yan G., Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 2006;96(12):67–72.
6. Corona G., Forti G., Maggi M. Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male 2008;11(4):193–9.
7. Zilov A. V., Sheilor I. M., Gusova A. A. Vozrastnoi gipogonadizm. Osobennosti diagnostiki, kliniki i lecheniya. Farmateka 2007;11:38–43.
8. Shabsigh R., Rajfer J., Aversa A. et al. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006;60(9):1087–92.
9. Alexandersen P., Haarbo J., Byrjalsen I. et al. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 1999;84(7):813–9.
10. Jones R. D. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs 2005;5(3):141–54.
11. Mohr B. A., Guay A. T., O'Donnell A. B., McKinlay J. B. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf)
12. ;62(1):64–73.
13. Goncharov N. P. Sovremennye metody gormonal'nogo analiza. Probl endokrinol 2011;57(1):86–91.
14. Goncharov N. P., Katsiya G. V. Diagnosticheskaya znachimost' opredeleniya obshchego testosterona v syvorotke i svobodnogo biologicheski aktivnogo testosterona v slyune u muzhchin. Probl endokrinol 2007;53(3):30–5.
15. Goncharov N. P. Znachenie i rol' metodov opredeleniya gormonov v razvitii endokrinologii kak obshchebiologicheskoi nauki. Vestn RAMN 2012;3:42–9.
16. Goncharov N. P., Katsiya G. V., Kolesnikova G. S., Dobracheva A. D. Gormonal'nyi analiz v diagnostike boleznei endokrinnykh zhelez. M.: Adamant\"\", 2009. S. 328.
17. Traish A. M., Kypreos K. E. Testosterone and cardiovascular disease: an old idea with modern clinical implications. Atherosclerosis 2011;214(2):244–8.
18. Wranicz J. K., Rosiak M., Cygankiewicz I. et al. Sex steroids and heart rate variability in patients after myocardial infarction. Ann Noninvasive Electrocardiol 2004;9(2):156–61.
19. Jankowska E. A., Biel B., Majda J. et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006;114(17):1829–37.
20. Gyllenborg J., Rasmussen S. L., Borch-Johnsen K. et al. Cardiovascular risk factors in men: The role of gonadal steroids and sex hormone-binding globulin. Metabolism 2001;50(8):882–8.
21. Goncharov N. P., Katsiya G. V., Chagina N. A. Ozhirenie i formirovanie metabolicheskogo sindroma u molodykh muzhchin s razvitiem androgennogo defitsita. Vestn RAMN 2009;7:20–6.
22. Tsai E. C. Low serum testosterone level as a predictor of increased visceral fat in Japenes-American men. Int J Obes Relat Metab Disord 2000;24:485–91.
23. Malkin C. J. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96(22):1821–5.
24. Morales A., Lunenfeld B. Androgen replacement therapy in aging men with secondary hypogonadism. Draft recommendations for endorsement by ISSAM. Aging Male 2001;4:151–62.
25. Dedov I. I. Primenenie Nebido pri sindrome gipogonadizma i ego oslozhneniyakh u muzhchin. Urologiya 2011;6:59–67.
26. Vermeulen A., Verdonck L., Kaufman J. M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–72.
27. Basaria S., Coviello A. D., Travison T. G. Adverse events associated with testosterone administration. N Engl J Med 2010;363(2):109–22.
28. Rosano G. M., Leonardo F., Pagnotta P. et al. Acute anti-ischaemic effect of testosterone in men with coronary artery disease. Circulation 1999;99:1666–70.
29. Kravchenko A. Ya., Provotorov V. M. Klinicheskii effekt testosterona pri stabil'noi ctenokardii u muzhchin. Rats farmakoter v kardiol 2009;1:37–41.
30. Pugh P. J. The prevalence of hypogonadism in men with coronary artery disease. J Am Coll Cardiol 2003;41:344–5.
31. Svartberg J., von Mühlen D., Schirmer H. et al. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø Study. Eur J Endocrinol 2004;150(1):65–71.
32. Giltay E. J., Tishova Y. A., Mskhalaya G. J. et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010;7(7):2572–82.
33. Moon du G., Park M. G., Lee S. W. et al. The efficacy and safety of testosterone undecanoate (Nebido (®) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med 2010;7(6):2253–60.
34. Legros J. J., Meuleman E. J., Elbers J. M. et al. Oral testosterone replacement in symptomatic late onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol 2009;160(5):821–31.
35. Morris P. D., Channer K. S. Testosterone and cardiovascular disease in men. Asian J Androl 2012;14(3):428–35.
36. Malkin C. J., Pugh P. J., Morris P. D. et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96:1821–5.
37. Pugh P. J., Jones T. H., Channer K. S. Acute haemodinamic effects of testosterone in men with chronic heart failure. Eur Heart J 2003;24:909–15.
38. Kravchenko A. Ya. Issledovanie vliyaniya vozrastnogo priobretennogo androgenodefitsita na techenie i osobennosti terapii serdechno-sosudistykh zabolevanii. Avtoref. dis. … d-ra med. nauk. Voronezh, 2010. S. 30
39. Gruenewald D. A.,Matsumoto A. M. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 2003;51:101–5.
40. Allan C. A., McLachlan R. I. Age-related changes in testosterone and the role of replacement therapy in older men. Clin Endocrinol 2004;60:653–70.
41. Haffner J. E., Moss S. E., Klein B. E. K., Klein R. Sex hormones and DHEASO4 in relation to ischemic heart disease in diabetic subjects. The WESDR Study. Diabetes Care 1996;19:1045–50.
42. Liverman C. T., Blazer D. G. (eds.). Testosterone and aging: clinical research directions. Washington, DC: Institute of Medicine. The National Academies Press, 2004.
43. Phillips G., Pinkernell B. H., Jing T. Y. The association between hypotestosteronemia and coronary heart disease in men. Arterioscler Thromb 1994;14:701–6.
44. Cauley J. A., Gutai J. P., Kuller L. H., Dai W. S. Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol 1987;60:771–7.
45. Goldberg R. B., Rabin A. N., Alexander A. N. et al. Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and Apo A and B. J Clin Endocrinol Metab 1985;60:203–7.
46. Simon H. B. Testosterone – The 'Heart'of the Matter Last. Reviewed by Faculty of Harvard Medical School on January 2013;24.
47. Saad F., Aversa A., Isidori A. M. et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675–85.
